A newly developed wearable patch system could make diagnostic testing for cystic fibrosis (CF) more accessible by replacing conventional sweat testing with a simpler, lower-cost approach that requires minimal equipment. Researchers report that the technology delivers results comparable to the current clinical standard while offering the potential to bring testing closer to patients, particularly in underserved regions.
Cystic fibrosis is a genetic disorder that primarily affects the lungs and digestive system. Early diagnosis is essential because timely treatment can significantly improve long-term health outcomes. However, standard sweat chloride testing is typically available only at accredited CF centers, limiting access for families living in rural areas or countries with fewer specialized healthcare facilities.
A simpler approach
The new system, called CF SWIFT, consists of two small, flexible skin patches designed to be comfortable even for newborns. The first patch stimulates sweat production using a mild chemical stimulant and a small battery-powered device. A second patch is then applied to collect the sweat sample.
Instead of requiring laboratory analysis, the collected sweat is evaluated using a smartphone application. The app analyzes subtle changes in color density within the collection patch to determine chloride concentrations, the key biomarker used to diagnose cystic fibrosis. The complete procedure takes less than an hour.
According to the research team, the integrated design represents an important advance over earlier prototypes by combining sweat stimulation and collection into a single, self-contained system. Developed by bioengineers at Northwestern University in collaboration with cystic fibrosis specialists at Ann & Robert H. Lurie Children's Hospital of Chicago, the technology is intended to simplify testing without compromising diagnostic accuracy.
Comparable performance
The study evaluated the wearable system in 55 participants, including healthy volunteers as well as children and young adults with cystic fibrosis or related conditions, ranging in age from infancy to 21 years. Each participant underwent both conventional sweat testing and testing with the wearable patches.
Researchers found a strong correlation between the chloride measurements obtained with the new device and those generated by the standard diagnostic method. These results suggest that the wearable system can reliably measure sweat chloride concentrations used for CF diagnosis.
The investigators emphasize, however, that additional validation will be required before the technology enters routine clinical practice. Future multicenter studies will focus particularly on younger infants, since most cystic fibrosis diagnoses are made within the first weeks of life following newborn screening. Regulatory approval will also be required before the system can be introduced into clinical care.
Access to early diagnosis
The researchers believe the greatest potential of the wearable technology lies in improving access to diagnostic testing. It is estimated that around half of people living with cystic fibrosis worldwide remain undiagnosed. Without treatment, life expectancy is dramatically reduced, whereas early diagnosis and modern therapies have substantially improved survival in countries where specialized care is available.
By reducing dependence on specialized laboratories and expert personnel, the wearable patches could enable testing in community healthcare settings and regions where conventional sweat testing is difficult to access. Beyond improving convenience, this approach could help shorten the time between newborn screening and confirmatory diagnosis, allowing treatment to begin earlier.
While larger validation studies are still needed, the results illustrate how wearable biosensor technologies and smartphone-based analysis are beginning to reshape diagnostic pathways. Rather than replacing specialist care, innovations such as CF SWIFT may help extend its reach, bringing reliable diagnostic testing closer to patients and supporting earlier intervention for a disease where every week can make a difference. The findings were published in npj Digital Medicine.
